VivoSeq
Oncology

Metastatic Prostate Cancer

239

Pipeline Programs↗

55

Active Trials↗

75

Companies Involved↗

Metastatic Prostate Cancer is a highly competitive landscape with 239 programs across 75 companies. The most active players are ORIC Pharmaceuticals, Ratio Therapeutics, Inc., Synta Pharmaceuticals Corp.. 12 therapies are approved with 41 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

84/100

Pipeline Velocity

30/100

Mech. Concentration

7/100

Completion Rate

77/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

ORIC Pharmaceuticals

5 programs

Phase 1R

Ratio Therapeutics, Inc.

2 programs

Phase 1S

Synta Pharmaceuticals Corp.

1 program

Phase 1B

Blue Earth Therapeutics Ltd

1 program

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1K

Kazia Therapeutics Limited

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical15

Dexamethasone

Aspen Global Incorporated

Celecoxib

Philadelphia Eye Associates

Apatinib

LaNova Medicines Zhejiang Co., Ltd.

Leuprorelin

Takeda

Fluorthanatrace

Washington University School of Medicine

Phase 134

Gefitinib

AstraZeneca

Filgrastim

Eastern Cooperative Oncology Group

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ipilimumab

Bristol-Myers Squibb

Cyclosporine

Novartis

Phase 2137

Leuprolide

AbbVie

Antineoplaston A10

Burzynski Research Institute

Zimberelimab

Arcus Biosciences

Nivolumab

Bristol-Myers Squibb

Trastuzumab

Organon and Co

Phase 341

Darolutamide

Bayer

Carboplatin

Avyxa

Methylprednisolone

Pfizer

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Docetaxel

Avyxa

Approved12

Testosterone Cypionate

Azurity Pharmaceuticals

Testosterone Enanthate

Antares Pharma Inc.

Talazoparib

Pfizer

Degarelix

Ferring

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

88%

Small molecule

211 of 239 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody115%Radiopharmaceutical63%Protein / enzyme31%Vaccine31%Cell therapy2<1%Antibody–drug conjugate1<1%Other2<1%

Small molecule leads; the ring shows all 239 classified programs, each share of the total. Modality classified for 96% of 270 pipeline programs.

Analysis

Trial Status

260

clinical trials

Completed145 · 56%
Terminated38 · 15%
Recruiting31 · 12%
Active, not recruiting20 · 8%
Unknown status16 · 6%
Withdrawn6 · 2%
Other4 · 2%

Clinical Trials

Trial Activity

260 trials

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Recruiting·FFundacion Oncosur·Phase 2·NCT06582628·78 enrolled
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
Recruiting·ZZhujiang Hospital·N/A·NCT04997252·50 enrolled
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06212583·88 enrolled
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Recruiting·UUNICANCER·Phase 3·NCT04916613·300 enrolled
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT05560659·92 enrolled
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Recruiting·SSun Yat-sen University·Phase 2·NCT06854250·104 enrolled
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Recruiting·AAdvanCell Pty Limited·Phase 1/2·NCT05720130·100 enrolled
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Recruiting·VVA Office of Research and Development·Phase 2/3·NCT04787744·464 enrolled
Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06343038·25 enrolled
A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer
Recruiting·—·Phase 1·NCT07096128·36 enrolled
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2/3·NCT03495427·60 enrolled
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
Recruiting·CCentre Jean Perrin·N/A·NCT06600802·120 enrolled
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
Recruiting·RRenJi Hospital·Phase 2/3·NCT06972511·120 enrolled
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Recruiting·SSanta Chiara Hospital·N/A·NCT06473259·3,000 enrolled
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06616597·58 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)